Ezzat, S., Asa, S. L., Couldwell, W. T., Barr, C. E., Dodge, W. E., Vance, M. L., & McCutcheon, I. E. (2004). The prevalence of pituitary adenomas: a systematic review. Cancer, 101(3), 613–619. https://doi-org.ucsf.idm.oclc.org/10.1002/cncr.20412

Ostrom, Q. T., Gittleman, H., Truitt, G., Boscia, A., Kruchko, C., & Barnholtz-Sloan, J. S. (2018). CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro-oncology, 20(suppl_4), iv1–iv86. https://doi-org.ucsf.idm.oclc.org/10.1093/neuonc/noy131

Raverot, G., Burman, P., McCormack, A., Heaney, A., Petersenn, S., Popovic, V., Trouillas, J., Dekkers, O. M., & European Society of Endocrinology (2018). European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. European journal of endocrinology, 178(1), G1–G24. https://doi-org.ucsf.idm.oclc.org/10.1530/EJE-17-0796

Trouillas, J., Jaffrain-Rea, M. L., Vasiljevic, A., Dekkers, O., Popovic, V., Wierinckx, A., McCormack, A., Petersenn, S., Burman, P., Raverot, G., & Villa, C. (2020). Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions. Reviews in endocrine & metabolic disorders, 21(2), 243–251. https://doi-org.ucsf.idm.oclc.org/10.1007/s11154-020-09562-9

Kontogeorgos, G., Thodou, E., Osamura, R. Y., & Lloyd, R. V. (2022). High-risk pituitary adenomas and strategies for predicting response to treatment. Hormones (Athens, Greece), 21(1), 1–14. https://doi-org.ucsf.idm.oclc.org/10.1007/s42000-021-00333-y

Trouillas, J., Roy, P., Sturm, N., Dantony, E., Cortet-Rudelli, C., Viennet, G., Bonneville, J. F., Assaker, R., Auger, C., Brue, T., Cornelius, A., Dufour, H., Jouanneau, E., François, P., Galland, F., Mougel, F., Chapuis, F., Villeneuve, L., Maurage, C. A., Figarella-Branger, D., … Tabarin, A. (2013). A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta neuropathologica, 126(1), 123–135. https://doi-org.ucsf.idm.oclc.org/10.1007/s00401-013-1084-y

Trouillas, J., Burman, P., McCormack, A., Petersenn, S., Popovic, V., Dekkers, O., & Raverot, G. (2018). Aggressive pituitary tumours and carcinomas: two sides of the same coin?. European journal of endocrinology, 178(6), C7–C9. https://doi-org.ucsf.idm.oclc.org/10.1530/EJE-18-0250

Asa S, Perry A. Tumors of the Pituitary Gland. AFIP Atlas of Tumor and Non-tumor Pathology, 5th series Fascicle 1. Arlington, VA: ARP Press; 2020.

Rindi, G., Klimstra, D. S., Abedi-Ardekani, B., Asa, S. L., Bosman, F. T., Brambilla, E., Busam, K. J., de Krijger, R. R., Dietel, M., El-Naggar, A. K., Fernandez-Cuesta, L., Klöppel, G., McCluggage, W. G., Moch, H., Ohgaki, H., Rakha, E. A., Reed, N. S., Rous, B. A., Sasano, H., Scarpa, A., … Cree, I. A. (2018). A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc, 31(12), 1770–1786. https://doi-org.ucsf.idm.oclc.org/10.1038/s41379-018-0110-y

Saeger, W., Mawrin, C., Meinhardt, M., Wefers, A. K., & Jacobsen, F. (2022). Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC?. Endocrine pathology, 33(2), 257–262. https://doi-org.ucsf.idm.oclc.org/10.1007/s12022-021-09693-y

Mete, O., & Lopes, M. B. (2017). Overview of the 2017 WHO Classification of Pituitary Tumors. Endocrine pathology, 28(3), 228–243. https://doi-org.ucsf.idm.oclc.org/10.1007/s12022-017-9498-z

Knosp, E., Steiner, E., Kitz, K., & Matula, C. (1993). Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery, 33(4), 610–618. https://doi-org.ucsf.idm.oclc.org/10.1227/00006123-199310000-00008

Hardy J. Transsphenoidal surgery of hypersecreting pituitary tumours. In: Kohler PO, Ross GT, editors. Diagnosis and Treatment of Pituitary Tumours. Int. Congress Series No. 303. Amsterdam: Exerpta Medica; 1973. p. 179–98

Raverot, G., Dantony, E., Beauvy, J., Vasiljevic, A., Mikolasek, S., Borson-Chazot, F., Jouanneau, E., Roy, P., & Trouillas, J. (2017). Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification. The Journal of clinical endocrinology and metabolism, 102(9), 3368–3374.https://doi-org.ucsf.idm.oclc.org/10.1210/jc.2017-00773

Lelotte, J., Mourin, A., Fomekong, E., Michotte, A., Raftopoulos, C., & Maiter, D. (2018). Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients. European journal of endocrinology, 178(3), 237–246.https://doi-org.ucsf.idm.oclc.org/10.1530/EJE-17-0965

Asioli, S., Righi, A., Iommi, M., Baldovini, C., Ambrosi, F., Guaraldi, F., Zoli, M., Mazzatenta, D., Faustini-Fustini, M., Rucci, P., Giannini, C., & Foschini, M. P. (2019). Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre. European journal of endocrinology, 180(2), 127–134. https://doi-org.ucsf.idm.oclc.org/10.1530/EJE-18-0749

Terry, M., Reis, G., Horvai, A., Pekmezci, M., & Perry, A. (2023). Sarcomatous Transformation of a Medically Treated Lactotroph Pituitary Neuroendocrine Tumor?. Endocrine pathology, 34(1), 161–163.https://doi-org.ucsf.idm.oclc.org/10.1007/s12022-023-09757-1

Duncan, V. E., Nabors, L. B., Warren, P. P., Conry, R. M., Willey, C. D., Perry, A., Riley, K. O., & Hackney, J. R. (2016). Primary Sellar Rhabdomyosarcoma Arising in Association With a Pituitary Adenoma. International journal of surgical pathology, 24(8), 753–756. https://doi-org.ucsf.idm.oclc.org/10.1177/1066896916658955

Rindi, G., Mete, O., Uccella, S., Basturk, O., La Rosa, S., Brosens, L. A. A., Ezzat, S., de Herder, W. W., Klimstra, D. S., Papotti, M., & Asa, S. L. (2022). Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocrine pathology, 33(1), 115–154. https://doi-org.ucsf.idm.oclc.org/10.1007/s12022-022-09708-2

Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., Soffietti, R., von Deimling, A., & Ellison, D. W. (2021). The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-oncology, 23(8), 1231–1251. https://doi-org.ucsf.idm.oclc.org/10.1093/neuonc/noab106

Lucas, C. G., Villanueva-Meyer, J. E., Whipple, N., Oberheim Bush, N. A., Cooney, T., Chang, S., McDermott, M., Berger, M., Cham, E., Sun, P. P., Putnam, A., Zhou, H., Bollo, R., Cheshier, S., Poppe, M. M., Fung, K. M., Sung, S., Glenn, C., Fan, X., Bannykh, S., … Solomon, D. A. (2020). Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic features. Brain pathology (Zurich, Switzerland), 30(3), 479–494. https://doi-org.ucsf.idm.oclc.org/10.1111/bpa.12797

Pasquel, F. J., Vincentelli, C., Brat, D. J., Oyesiku, N. M., & Ioachimescu, A. G. (2013). Pituitary carcinoma in situ. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 19(3), e69–e73. https://doi-org.ucsf.idm.oclc.org/10.4158/EP12351.CR

Guo, F., Wang, G., Wang, F., Xu, D., & Liu, X. (2018). Identification of Novel Genes Involved in the Pathogenesis of an ACTH-Secreting Pituitary Carcinoma: A Case Report and Literature Review. Frontiers in oncology, 8, 510. https://doi-org.ucsf.idm.oclc.org/10.3389/fonc.2018.00510

Guaraldi, F., Morandi, L., Zoli, M., Mazzatenta, D., Righi, A., Evangelisti, S., Ambrosi, F., Tonon, C., Giannini, C., Lloyd, R. V., & Asioli, S. (2022). Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients. Clinical endocrinology, 97(6), 763–772. https://doi-org.ucsf.idm.oclc.org/10.1111/cen.14827

Miyake, Y., Adachi, J. I., Suzuki, T., Mishima, K., Araki, R., Mizuno, R., & Nishikawa, R. (2019). TERT promoter methylation is significantly associated with TERT upregulation and disease progression in pituitary adenomas. Journal of neuro-oncology, 141(1), 131–138. https://doi-org.ucsf.idm.oclc.org/10.1007/s11060-018-03016-8